Relay Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Relay Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-119.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 84% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$100Sales grew 1,012% in 3 years; of every extra $100 of sales, $100 became extra profit.
Higher than 80% of Healthcare companies in United States.
Asset Productivity Ratio
+1012% / -44%In 3 years sales changed by +1012% while total assets changed by -44%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-62.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 77% of Healthcare companies in United States.
Cash Cushion Ratio
+13%Cash, after subtracting all debt, equals 13% of its market value (net cash).
Higher than 54% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than almost all Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Relay Therapeutics, Inc. made a loss over the last year. Relay Therapeutics, Inc. owes $0.08 for every $1 it owns. Relay Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRelay Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.52The share price is 4.52 times Relay Therapeutics, Inc.'s book value per share, higher than 69% of Healthcare companies in United States.
Market cap
$4.0 BThe total market value of all of Relay Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 82% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$890 MWhat Relay Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.06Net worth divided by the number of shares. The share price of $18.34 is 4.5 times this, which is the P/B above.
Return on equity (ROE)
-36.8%Relay Therapeutics, Inc. lost 36.8% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
Owes vs Owns
0.08×Relay Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Dividend yield
NoneRelay Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+53%Revenue rose 53% in the year to Dec 2025, and grew 123% a year on average over 3 years.
Profit growth
LossRelay Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-1800.6%Relay Therapeutics, Inc. lost $1801 for every $100 of revenue.
Cash vs debt
Net cashRelay Therapeutics, Inc. held $522 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Relay Therapeutics, Inc.: $4.0 B ÷ $890 M (30 Jun 2026) = 4.5.
What is Relay Therapeutics, Inc.'s return on equity?
Relay Therapeutics, Inc. lost 36.8% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
How much does Relay Therapeutics, Inc. owe compared with what it owns?
Relay Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Does Relay Therapeutics, Inc. pay a dividend?
No. Relay Therapeutics, Inc. does not currently pay a dividend.
Is Relay Therapeutics, Inc.'s revenue growing?
Revenue rose 53% in the year to Dec 2025, and grew 123% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.